Comac Medical is pleased to announce our participation in EUCROF 2026, taking place in February 2026, bringing together key stakeholders from across Europe’s clinical research and life sciences ecosystem. EUCROF is a leading forum for dialogue between regulators, CROs, sponsors, and policy-makers, focused on shaping the future of clinical research in Europe.

Representing Comac Medical, Chris Smyth, CEO, will take part as a speaker in Plenary 3: Biotech Act, Life Sciences Strategy and Regulatory Evolution, contributing to the session “Biotech Act, Life Sciences Strategy and Regulatory Evolution: The CRO perspective.” This plenary session will explore the evolving European regulatory landscape, the upcoming EU Biotech Act, and the implications for clinical development and innovation from a CRO standpoint.

Chris Smyth will share his perspective on how regulatory evolution and life sciences strategy can support more efficient, competitive, and patient-centric clinical research across Europe, drawing on the company’s extensive experience in global clinical development.

At Comac Medical, we remain committed to advancing clinical development through regulatory expertise, operational excellence, and close collaboration with sponsors, regulators, and industry partners.

📅 Session highlight
Plenary 3: Biotech Act, Life Sciences Strategy and Regulatory Evolution
Date: Tuesday, February 3, 2026
Time: 9:00 AM – 10:30 AM (Europe/Amsterdam)
Talk: Biotech Act, Life Sciences Strategy and Regulatory Evolution: The CRO perspective

We look forward to engaging with peers and stakeholders at EUCROF 2026 and contributing to the conversation on the future of clinical research in Europe.